AUTO-3 |
AUTO-3 |
Phase 2 Clinical |
University College London |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
GC-022 |
GC-022; GC-022F |
Phase 2 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
Anti CD22 CAR-T cell therapy (Shanghai Yake Biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd, The First Affiliated Hospital Of Zhejiang University School Of Medicine, Beijing Gao Boren Hospital Co Ltd, Chengdu USino Technology Biology Co Ltd |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CART22-cells |
CART22-cells; JJO686 |
Phase 2 Clinical |
Novartis Pharma Ag, University Of Pennsylvania |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
Anti-CD22-CAR T cell therapy (Kecellitics Biotech) |
|
Phase 2 Clinical |
Kecellitics Biotech Company Ltd |
Lymphoma, B-Cell; Leukemia; Lymphoma |
Details
|
Epratuzumab-cys-tesirine |
ADCT-602 |
Phase 2 Clinical |
Adc Therapeutics Sa |
Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Philadelphia Chromosome |
Details
|
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Leukemia; Lymphoma |
Details
|
Anti-CD22 CAR-T cell therapy (No. 307 Hospital) |
|
Phase 2 Clinical |
The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital) |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
UCART-20x22 |
UCART-20x22 |
Phase 2 Clinical |
Cellectis Sa |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-T |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma |
Details
|
Fourth-gen CAR T Cells Targeting CD19/CD22 therapy(Essen Biotech) |
|
Phase 2 Clinical |
Essen Biotech |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma; Central Nervous System Lymphoma |
Details
|
CD19/CD22 Bispecific CAR-T Cell Therapy(Beijing Tongren Hospital) |
|
Phase 2 Clinical |
Beijing Tongren Hospital, Cmu |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19/CD22 CAR-T cell therapy (The First Affiliated Hospital Of Soochow University) |
|
Phase 2 Clinical |
The First Affiliated Hospital Of Soochow University |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) |
|
Phase 2 Clinical |
Kk Women'S And Children'S Hospital |
Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Bispecific CD19/22 CAR T cells |
|
Phase 2 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
anti-CD22-CAR-transduced T cells(Southwest Hospital) |
|
Phase 2 Clinical |
Southwest Hospital |
Leukemia; Lymphoma |
Details
|
CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) |
4SCAR19/22 |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) |
CT-120 |
Phase 2 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
CD19/CD22 dual-target CAR-T (Yake biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Burkitt Lymphoma |
Details
|
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) |
|
Phase 2 Clinical |
Shanghai Ultra-T Immune Therapeutics Co LTD |
Leukemia, B-Cell |
Details
|
SCRI-CAR22v2 |
|
Phase 2 Clinical |
Seattle Children'S Hospital |
Leukemia; Lymphoma |
Details
|
CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) |
|
Phase 2 Clinical |
Federal Research Institute of Pediatric Hematology Oncology and Immunology |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma |
Details
|
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) |
|
Phase 2 Clinical |
The University Of Texas MD Anderson Cancer Center |
Candidiasis, Vulvovaginal; Neoplasm, Residual; Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) |
|
Phase 2 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Pancreatic Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
TRPH-222 |
CD22-4AP; TRPH-222; CAT-02-106 |
Phase 1 Clinical |
Catalent Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) |
|
Phase 1 Clinical |
Shanghai Jiaotong University, Shanghai General Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) |
|
Phase 1 Clinical |
Stanford University, Orca Biosystems Inc |
Candidiasis, Vulvovaginal; Leukemia, Myelogenous, Chronic; Neoplasm, Residual; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Philadelphia Chromosome |
Details
|
CD22-CART |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Lymphoma, B-Cell, Marginal Zone; Leukemia, Hairy Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Waldenstrom Macroglobulinemia |
Details
|
Anti-CD19/CD22 CAR-T cell therapy (Shenzhen BinDeBio) |
|
Phase 1 Clinical |
Dehe Biotech Co Ltd |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD22 CAR T cell therapy (Shanghai GeneChem) |
|
Phase 1 Clinical |
Shanghai Genechem Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19- and CD22 specific CAR (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Leukemia; Lymphoma |
Details
|
RD-102 |
RD-102 |
Phase 1 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse |
Details
|
Anti-CD22/CD19 monoclonal antibody-toxin conjugate |
|
Phase 1 Clinical |
The University Of Texas Southwestern Medical Center |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
B-019 |
B-019 |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Leukemia, Lymphoid; Central Nervous System Lymphoma |
Details
|
BAY-1862864 |
BAY-1862864 |
Phase 1 Clinical |
Bayer AG |
Lymphoma, Non-Hodgkin |
Details
|
Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy(Beijing GoBroad Hospital) |
|
Phase 1 Clinical |
Beijing GoBroad Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Allogeneic CD22-directed CAR T Cell Therapy(Sana Biotechnology) |
SC262; SC-262 |
Phase 1 Clinical |
Sana Biotechnology Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
AUTO-1-NG |
AUTO-1-NG; AUTO1/22 |
Phase 1 Clinical |
Autolus Therapeutics Plc, University College London |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma |
Details
|
Autologous CD22 targeting CAR-T cells therapy(British Columbia Cancer Agency) |
CLIC-2201 |
Phase 1 Clinical |
British Columbia Cancer Agency |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) |
|
Phase 1 Clinical |
Persongen Biotherapeutics |
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Neoplasms, Plasma Cell |
Details
|
CD22 CAR-T Cell Therapy (Hebei Senlang Biotechnology) |
|
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Solid tumours; Sarcoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
REGN5837 |
REGN5837; REGN-5837 |
Phase 1 Clinical |
|
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
bispecific CD19/CD22 CAR T-cell therapy (University of Colorado) |
|
Phase 1 Clinical |
University Of Colorado |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
LCAR-AIO |
LCAR-AIO; VHH CAR-T |
Phase 1 Clinical |
|
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
ThisCAR-T-22(Fundamenta Therapeutics) |
ThisCAR-T-22 |
Phase 1 Clinical |
Fundamenta Therapeutics Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) |
|
Phase 1 Clinical |
University Of Colorado, Denver, Usa |
Lymphoma, Non-Hodgkin |
Details
|
CAR-20-19-22 |
CAR-20-19-22 |
Phase 1 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) |
HX-s001; YTS101; HX-s001/YTS101; HXYT-001 |
Phase 1 Clinical |
Beijing Qingyi Taike Pharmaceutical Technology Co Ltd |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
HY-004 (Juventas) |
HY-004 (Juventas) |
Phase 1 Clinical |
Juventas Cell Therapy Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti-human CD19-CD22 T cell therapy |
HR004 |
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Central Nervous System Lymphoma |
Details
|
Rezetamig |
JNJ-8780; JNJ75348780; JNJ-75348780 |
Phase 1 Clinical |
Teneobio Inc |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19/CD22-Dual-STAR-T cell therapy (Hebei Yanda Ludaopei Hospital) |
|
Phase 1 Clinical |
Hebei Yanda Ludaopei Hospital |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) |
|
Phase 1 Clinical |
Wuhan BioRaid Biotechnology Co Ltd |
Lymphoma, B-Cell; Multiple Myeloma |
Details
|
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University, Shanghai YaKe Biotechnology Co Ltd |
Hematologic Neoplasms |
Details
|
UCART-22 |
UCART-22 |
Phase 1 Clinical |
Cellectis Sa |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
JCAR-018 |
JCAR-018 |
Phase 1 Clinical |
National Cancer Institute, Opus Bio |
Lymphoma, B-Cell; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma, Large-Cell, Anaplastic |
Details
|
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) |
|
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
CTA-101 |
CTA-101 |
Phase 1 Clinical |
Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
AUTO-3 |
AUTO-3 |
Phase 2 Clinical |
University College London |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
GC-022 |
GC-022; GC-022F |
Phase 2 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
Anti CD22 CAR-T cell therapy (Shanghai Yake Biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd, The First Affiliated Hospital Of Zhejiang University School Of Medicine, Beijing Gao Boren Hospital Co Ltd, Chengdu USino Technology Biology Co Ltd |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CART22-cells |
CART22-cells; JJO686 |
Phase 2 Clinical |
Novartis Pharma Ag, University Of Pennsylvania |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
Anti-CD22-CAR T cell therapy (Kecellitics Biotech) |
|
Phase 2 Clinical |
Kecellitics Biotech Company Ltd |
Lymphoma, B-Cell; Leukemia; Lymphoma |
Details
|
Epratuzumab-cys-tesirine |
ADCT-602 |
Phase 2 Clinical |
Adc Therapeutics Sa |
Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Philadelphia Chromosome |
Details
|
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Leukemia; Lymphoma |
Details
|
Anti-CD22 CAR-T cell therapy (No. 307 Hospital) |
|
Phase 2 Clinical |
The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital) |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
UCART-20x22 |
UCART-20x22 |
Phase 2 Clinical |
Cellectis Sa |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-T |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma |
Details
|
Fourth-gen CAR T Cells Targeting CD19/CD22 therapy(Essen Biotech) |
|
Phase 2 Clinical |
Essen Biotech |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma; Central Nervous System Lymphoma |
Details
|
CD19/CD22 Bispecific CAR-T Cell Therapy(Beijing Tongren Hospital) |
|
Phase 2 Clinical |
Beijing Tongren Hospital, Cmu |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19/CD22 CAR-T cell therapy (The First Affiliated Hospital Of Soochow University) |
|
Phase 2 Clinical |
The First Affiliated Hospital Of Soochow University |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) |
|
Phase 2 Clinical |
Kk Women'S And Children'S Hospital |
Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Bispecific CD19/22 CAR T cells |
|
Phase 2 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
anti-CD22-CAR-transduced T cells(Southwest Hospital) |
|
Phase 2 Clinical |
Southwest Hospital |
Leukemia; Lymphoma |
Details
|
CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) |
4SCAR19/22 |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) |
CT-120 |
Phase 2 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
CD19/CD22 dual-target CAR-T (Yake biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Burkitt Lymphoma |
Details
|
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) |
|
Phase 2 Clinical |
Shanghai Ultra-T Immune Therapeutics Co LTD |
Leukemia, B-Cell |
Details
|
SCRI-CAR22v2 |
|
Phase 2 Clinical |
Seattle Children'S Hospital |
Leukemia; Lymphoma |
Details
|
CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) |
|
Phase 2 Clinical |
Federal Research Institute of Pediatric Hematology Oncology and Immunology |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma |
Details
|
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) |
|
Phase 2 Clinical |
The University Of Texas MD Anderson Cancer Center |
Candidiasis, Vulvovaginal; Neoplasm, Residual; Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) |
|
Phase 2 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Pancreatic Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
TRPH-222 |
CD22-4AP; TRPH-222; CAT-02-106 |
Phase 1 Clinical |
Catalent Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) |
|
Phase 1 Clinical |
Shanghai Jiaotong University, Shanghai General Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) |
|
Phase 1 Clinical |
Stanford University, Orca Biosystems Inc |
Candidiasis, Vulvovaginal; Leukemia, Myelogenous, Chronic; Neoplasm, Residual; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Philadelphia Chromosome |
Details
|
CD22-CART |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Lymphoma, B-Cell, Marginal Zone; Leukemia, Hairy Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Waldenstrom Macroglobulinemia |
Details
|
Anti-CD19/CD22 CAR-T cell therapy (Shenzhen BinDeBio) |
|
Phase 1 Clinical |
Dehe Biotech Co Ltd |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD22 CAR T cell therapy (Shanghai GeneChem) |
|
Phase 1 Clinical |
Shanghai Genechem Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19- and CD22 specific CAR (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Leukemia; Lymphoma |
Details
|
RD-102 |
RD-102 |
Phase 1 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse |
Details
|
Anti-CD22/CD19 monoclonal antibody-toxin conjugate |
|
Phase 1 Clinical |
The University Of Texas Southwestern Medical Center |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
B-019 |
B-019 |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Leukemia, Lymphoid; Central Nervous System Lymphoma |
Details
|
BAY-1862864 |
BAY-1862864 |
Phase 1 Clinical |
Bayer AG |
Lymphoma, Non-Hodgkin |
Details
|
Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy(Beijing GoBroad Hospital) |
|
Phase 1 Clinical |
Beijing GoBroad Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Allogeneic CD22-directed CAR T Cell Therapy(Sana Biotechnology) |
SC262; SC-262 |
Phase 1 Clinical |
Sana Biotechnology Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
AUTO-1-NG |
AUTO-1-NG; AUTO1/22 |
Phase 1 Clinical |
Autolus Therapeutics Plc, University College London |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma |
Details
|
Autologous CD22 targeting CAR-T cells therapy(British Columbia Cancer Agency) |
CLIC-2201 |
Phase 1 Clinical |
British Columbia Cancer Agency |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) |
|
Phase 1 Clinical |
Persongen Biotherapeutics |
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Neoplasms, Plasma Cell |
Details
|
CD22 CAR-T Cell Therapy (Hebei Senlang Biotechnology) |
|
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Solid tumours; Sarcoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
REGN5837 |
REGN5837; REGN-5837 |
Phase 1 Clinical |
|
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
bispecific CD19/CD22 CAR T-cell therapy (University of Colorado) |
|
Phase 1 Clinical |
University Of Colorado |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
LCAR-AIO |
LCAR-AIO; VHH CAR-T |
Phase 1 Clinical |
|
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
ThisCAR-T-22(Fundamenta Therapeutics) |
ThisCAR-T-22 |
Phase 1 Clinical |
Fundamenta Therapeutics Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) |
|
Phase 1 Clinical |
University Of Colorado, Denver, Usa |
Lymphoma, Non-Hodgkin |
Details
|
CAR-20-19-22 |
CAR-20-19-22 |
Phase 1 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) |
HX-s001; YTS101; HX-s001/YTS101; HXYT-001 |
Phase 1 Clinical |
Beijing Qingyi Taike Pharmaceutical Technology Co Ltd |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
HY-004 (Juventas) |
HY-004 (Juventas) |
Phase 1 Clinical |
Juventas Cell Therapy Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti-human CD19-CD22 T cell therapy |
HR004 |
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Central Nervous System Lymphoma |
Details
|
Rezetamig |
JNJ-8780; JNJ75348780; JNJ-75348780 |
Phase 1 Clinical |
Teneobio Inc |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19/CD22-Dual-STAR-T cell therapy (Hebei Yanda Ludaopei Hospital) |
|
Phase 1 Clinical |
Hebei Yanda Ludaopei Hospital |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) |
|
Phase 1 Clinical |
Wuhan BioRaid Biotechnology Co Ltd |
Lymphoma, B-Cell; Multiple Myeloma |
Details
|
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University, Shanghai YaKe Biotechnology Co Ltd |
Hematologic Neoplasms |
Details
|
UCART-22 |
UCART-22 |
Phase 1 Clinical |
Cellectis Sa |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
JCAR-018 |
JCAR-018 |
Phase 1 Clinical |
National Cancer Institute, Opus Bio |
Lymphoma, B-Cell; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma, Large-Cell, Anaplastic |
Details
|
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) |
|
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
CTA-101 |
CTA-101 |
Phase 1 Clinical |
Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|